Press releases
GeNeuro SA obtains the opening of debt-restructuring proceedings
Geneva, Switzerland, 30 September 2024 – 7:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – G NRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has approved its application for a debt-restructuring moratorium dated July 15, 2024, aimed at restructuring its debts and finding solutions for the continuity of its activities in the interests of all stakeholders.
GeNeuro announces that it submits a request for a debt moratorium to the Geneva Court of First Instance
Geneva, Switzerland, July 15, 2024 – 7:00 am CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or COVID-Long), announces that it will submit today to the Geneva Court of First Instance a request for a debt moratorium to restructure its debts and find solutions for the continuity of its activities in the interests of all stakeholders
GeNeuro announces the results of the GNC-501 in post-COVID-19 syndrome
Geneva, Switzerland, June 28, 2024 – 7:00 am CEST – The GNC-501 clinical trial is a Phase 2 study in patients suffering from post-COVID-19 neuropsychiatric syndromes, testing temelimab against placebo. The study enrolled over 200 patients in Switzerland, Spain and Italy who had tested positive for HERV-W ENV. The top-line results from this study show that treated patients had no clinically meaningful improvement compared to placebo on the primary endpoint measuring the improvement of fatigue with the PROMIS SF7a test. The majority of secondary endpoints did not show an effect either. The treatment was very well tolerated and safe, consistent with previous clinical trials in other indications.
GeNeuro Announces Approval of all Resolutions Proposed at 12 June 2024 Annual General Meeting
GeNeuro Announces Approval of all Resolutions
Proposed at 2024 Annual General Meeting
Geneva, Switzerland, June 14, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of 12 June 2024.
/https://geneuro.ch/wp-content/uploads/GeNeuro_AGM_14062024-EN.pdf
GeNeuro Announces Last Patient Last Visit in its Post-COVID Trial and Confirms Top-Line Results by End of June 2024
Geneva, Switzerland, May 16, 2024 – 8.00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing therapies for patients with neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post- Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced that the last patient enrolled in the GNC-501 trial of temelimab against post-COVID has now completed the study.
GeNeuro publishes its 2023 Universal Registration Document
Geneva, Switzerland, May 2, 2024 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID- 19, (PASC, post-COVID or Long-COVID), publishes its 2023 Universal Registration Document, in English, which has been filed on April 30, 2024 with the “Autorité des Marchés Financiers (AMF)”.